2016
DOI: 10.1080/17530350.2016.1258001
|View full text |Cite
|
Sign up to set email alerts
|

Values in motion: anti-counterfeiting measures and the securitization of pharmaceutical flows

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
10
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(11 citation statements)
references
References 20 publications
0
10
0
Order By: Relevance
“…In 2008, Kenya passed an Anti-counterfeit Act, which prevented the damage caused by products such as fake medicines (Quet, 2017). However, there have been controversies in the country in which a thin line exists between counterfeit drugs and parallel importation which brings challenges in the business environment of the pharmaceutical industry.…”
Section: Issn: 2664-9462mentioning
confidence: 99%
See 2 more Smart Citations
“…In 2008, Kenya passed an Anti-counterfeit Act, which prevented the damage caused by products such as fake medicines (Quet, 2017). However, there have been controversies in the country in which a thin line exists between counterfeit drugs and parallel importation which brings challenges in the business environment of the pharmaceutical industry.…”
Section: Issn: 2664-9462mentioning
confidence: 99%
“…From the viewpoint of the pharmaceutical industry, there is the view that allowing parallel importation of pharmaceuticals slows down the development of new pharmaceuticals. This hinders the pace of innovation in the industry, which, in turn, hinders not only the performance of the pharmaceutical industry but also the performance of individual pharmaceutical companies (Quet, 2017). In lieu of this, the companies, therefore, seek to ensure that strong patents for pharmaceutical products are implemented on a global scale so as to ban parallel trade.…”
Section: Issn: 2664-9462mentioning
confidence: 99%
See 1 more Smart Citation
“…It is also this tension that animates the politics of the medical copy and reconfigures questions about access to medication, and which value, health, or financial, is attached to the distinction between the good copy and the bad. Drug security further intervenes in this double bind and offers new possibilities for creating value (Quet ). While drug security efforts by the pharmaceutical industry aim at protecting the existing value of their medication, the concern for drug security produces, in the form of suspicion and association, new value not just for the industry but other agents as well, such as security personnel and traders and perhaps even consumers.…”
Section: Introductionmentioning
confidence: 99%
“…Perhaps due to the fact that pharmaceuticals are one of the most widespread and lucrative objects on Earth, however, specialized anthropological works have paid considerable attention toand considerably complicatedthe economy of drugs. Pharmaceutical value is produced through drug development, clinical trials or regimes of intellectual property and benefit sharing (Hayden 2003, 2007, Sunder Rajan 2006; it is forged by inducing patients to consume more drugs thus generating a surplus (Dumit 2012a, Sunder Rajan 2017; it involves investors evaluating profits and growth (Peterson 2016): it has shifted due to current emphasis on distribution and control rather than production (Quet 2016). In many of these cases, values may be plural but remain firmly anchored in a monetary reasoning.…”
mentioning
confidence: 99%